Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: BIOLOGICAL: pertuzumab|BIOLOGICAL: Trastuzumab emtansine [Kadcyla]
Sponsor: Genentech, Inc.